Blood Cancer Journal (Sep 2022)
The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
- Peiyu Yang,
- Fan Zhou,
- Yujun Dong,
- Guangxun Gao,
- Hua Xue,
- Xinyue Liang,
- Shanshan Yu,
- Weiling Xu,
- Yanping Ma,
- Xiaoqi Qin,
- Mengyao Li,
- Yun Dai,
- Fengyan Jin
Affiliations
- Peiyu Yang
- Department of Hematology, the First Hospital of Jilin University
- Fan Zhou
- Department of Hematology and Oncology, Shanghai Jing’an District Zhabei Central Hospital
- Yujun Dong
- Department of Hematology, Peking University First Hospital
- Guangxun Gao
- Department of Hematology, Xijing Hospital, Air Force Medical University
- Hua Xue
- Department of Hematology, the Affiliated Hospital of Hebei University
- Xinyue Liang
- Department of Hematology, the First Hospital of Jilin University
- Shanshan Yu
- Department of Hematology, the First Hospital of Jilin University
- Weiling Xu
- Department of Radiology, the First Hospital of Jilin University
- Yanping Ma
- Department Hematology, the Second Hospital of Shanxi Medical University
- Xiaoqi Qin
- Department Hematology, the Second Hospital of Shanxi Medical University
- Mengyao Li
- Department of Hematology, the First Hospital of Jilin University
- Yun Dai
- Laboratory of Cancer Precision Medicine, the First Hospital of Jilin University
- Fengyan Jin
- Department of Hematology, the First Hospital of Jilin University
- DOI
- https://doi.org/10.1038/s41408-022-00731-4
- Journal volume & issue
-
Vol. 12,
no. 9
pp. 1 – 4
Abstract
No abstracts available.
